tiprankstipranks
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Holding AKBA?
Track your performance easily

Akebia Therapeutics (AKBA) Ownership - Who Owns Akebia Therapeutics?

1,311 Followers

Akebia Therapeutics (AKBA) Ownership Overview

11.59%7.19%4.36%9.21%67.65%
11.59% Insiders
4.36% Other Institutional Investors
9.21% ETFs
67.65% Public Companies and
Individual Investors
The ownership structure of Akebia Therapeutics (AKBA) stock is a mix of institutional, retail, and individual investors. Approximately 20.76% of the company’s stock is owned by Institutional Investors, 11.59% is owned by Insiders, and 67.65% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
May 09, 2024
Steven Keith Burke
Svp, Chief Medical Officer
xxxxxxxxxxxxx
$31050
Mar 01, 2024
Nicole Hadas
Svp, Clo
xxxxxxxxxxxxx
$9439
Mar 01, 2024
Michel Dahan
Svp, Coo
xxxxxxxxxxxxx
$13684
Mar 01, 2024
Steven Keith Burke
Svp, Chief Medical Officer
xxxxxxxxxxxxx
$11327

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
16,205,119Insider8.60%29,493,317
9,660,079Institution4.43%17,581,344
8,948,783Institution4.10%16,286,785
7,939,047Institution3.64%14,449,066
2,364,436Insider1.08%4,303,274
2,204,911Institution1.01%4,012,938
1,921,647Institution0.88%3,497,398
1,000,735Institution0.46%1,821,338
809,713Institution0.37%1,473,678
672,092Insider0.31%1,223,207

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,939,047Institution3.64%14,449,066
2,204,911Institution1.01%4,012,938
1,921,647Institution0.88%3,497,398
1,000,735Institution0.46%1,821,338
809,713Institution0.37%1,473,678
570,974Institution0.26%1,039,173
396,648Institution0.18%721,899
282,396Institution0.13%513,961
119,228Institution0.05%216,995
107,700Institution0.05%196,014

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
5,953,172Institution2.73%10,834,773
5,945,188Institution2.72%9,869,012
2,602,859Institution1.19%4,320,746
1,798,739Institution0.82%3,273,705
948,403Institution0.43%1,574,349
473,502Institution0.22%861,774
454,074Institution0.21%826,415
411,249Institution0.19%748,473
197,054Institution0.09%358,638
183,022Institution0.08%333,100

FAQ

Who Owns Akebia Therapeutics (AKBA)?
According to the latest TipRanks data, approximately 4.36% of the company's stock is held by institutional investors, 11.59% is held by insiders, and 67.65% is held by retail investors.
    What percentage of Akebia Therapeutics (AKBA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 4.36% of Akebia Therapeutics (AKBA) stock is held by institutional investors.
      What percentage of Akebia Therapeutics (AKBA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 67.65% of Akebia Therapeutics (AKBA) stock is held by retail investors.
        Who owns the most shares of Akebia Therapeutics (AKBA)?
        Satter Muneer A owns the most shares of Akebia Therapeutics (AKBA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis